title: Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience.
abstract: 87 patients with high risk of recurrence FIGO stage I and II ovarian carcinoma were treated with adjuvant chemotherapy consisting of cisplatin 50 mg/m2 plus cyclophosphamide 600 mg/m2 on day 1 every 28 days for 6 courses. Toxicity and efficacy of the regimen was evaluated after a median follow-up of 45 months. Treatment-related toxicity was mild and reversible, consisting chiefly of acute WHO grade 2 myelosuppression (10% of patients) and controllable grade 3 emesis (55%). No late toxicity was observed. Actuarial 7-year survival and relapse-free survival (RFS) were 76% and 61%, respectively; a statistically significant difference in outcome was observed for undifferentiated grade tumour (G1 vs. G2 vs. G3: P less than 0.01) but not for FIGO stage disease (stage I vs. stage II). In our opinion, short-term chemotherapy including the most active single agent, i.e. cisplatin, appears a tolerable and effective treatment which deserves further evaluation in large randomised trials.
authors.affiliation: Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Chiara
authors.forename: S
authors.initials: S
authors.lastname: Mammoliti
authors.forename: C
authors.initials: C
authors.lastname: Oliva
authors.forename: L
authors.initials: L
authors.lastname: Merlini
authors.forename: M
authors.initials: M
authors.lastname: Bruzzone
authors.forename: M R
authors.initials: MR
authors.lastname: Sertoli
authors.forename: G C
authors.initials: GC
authors.lastname: Parodi
authors.forename: N
authors.initials: N
authors.lastname: Ragni
authors.forename: G
authors.initials: G
authors.lastname: Foglia
authors.forename: F
authors.initials: F
authors.lastname: Odicino
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D013997:Time Factors
chemical_list: D003520:Cyclophosphamide; D002945:Cisplatin